GlobeNewswire Inc.··NaAcumen Pharma Eyes Alzheimer's Breakthrough as Q1 Results Loom
Acumen Pharmaceuticals to report Q1 2026 results May 12, with Phase 2 Alzheimer's drug data expected later this year.
HALOABOSclinical-stage biopharmaceuticalAlzheimer's disease